Ondine Biomedical, Inc. (GB:OBI) has released an update.
Ondine Biomedical, Inc. reports an urgent need for alternative antimicrobial solutions as antibiotic resistance soars, with one-third of organisms causing healthcare-associated infections (HAIs) showing resistance. The company’s Steriwave technology, now in use across Canada and the NHS, presents a promising solution by effectively destroying pathogens without promoting resistance. With over 150,000 patients treated and no serious side effects reported, Steriwave’s adoption in Spanish hospitals marks a significant step in combating the global health threat of antimicrobial resistance.
For further insights into GB:OBI stock, check out TipRanks’ Stock Analysis page.
